I-Dxd: Clinical Trials

3 trials of I-Dxd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 3

Follow I-Dxd: new trials by email Literature Review of I-Dxd trials Research Report on I-Dxd

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms
Phase 3RecruitingMerck Sharp & Dohme LLC14402025-05-132026-10-30
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Ifinatamab deruxtecan, Docetaxel, Paclitaxel - Esophageal Squamous Cell Carcinoma
Phase 3RecruitingDaiichi Sankyo5102025-03-272026-10-26
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer
Phase 3RecruitingDaiichi Sankyo5402024-05-212026-08-06

Conditions studied

Esophageal Squamous Cell Carcinoma (1)  ·  Prostatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Daiichi Sankyo (2)  ·  Merck Sharp & Dohme LLC (1)

Countries

China (3)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Japan (3)  ·  Netherlands (3)  ·  Poland (3)  ·  South Korea (3)  ·  Spain (3)  ·  Taiwan (3)  ·  United States (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Brazil (2)

Results publications

PMID 41055143

NIH funding

2023 (2)